SACRAMENTO, Calif. —

Gov. Gavin Newsom has tested positive for COVID-19, just 10 days after receiving his second booster vaccine.

He tweeted his positive test results on Saturday, saying he tested this morning. Newsom had just met with New Zealand's prime minister on Friday in San Francisco's Golden Gate Park. Prime Minister Jacinda Ardern tested positive for the virus earlier in May.

California's governor said he is experiencing mild symptoms and is following health guidelines, including isolating and working remotely.

Newsom's press office said in a statement that he will be in isolation until at least June 2 and until he tests negative.

"Grateful to be vaccinated and for treatments like Paxlovid," Newsom said in a tweet.

He will be getting a prescription for Paxlovid and will start a five-day regimen immediately, according to his press office's statement.

Paxlovid is a treatment for mild-to-moderate symptoms in adults and children ages 12 and older, and is approved by the Food and Drug Administration. California distributes the treatment to some health providers, and has been working to expand access to free Paxlovid treatments through 'test to treat' sites for all those who test positive for COVID-19.

Newsom is vaccinated and has received two booster shots, his most recent shot was on May 18. Health officials say COVID-19 vaccines won't completely block infection, but that the shots are mainly designed to prevent severe illness.

WASHINGTON — The U.S. has authorized the first pill against COVID-19, a Pfizer drug that Americans can take at home to reduce the risk of hospitalization and death.

The Food and Drug Administration announcement comes as the U.S. braces for a wave of new infections from the omicron variant that is threatening already-strained hospitals.

Pfizer's prescription pill, which it calls Paxlovid, is the first U.S. medication that doesn't require an injection or an IV, a long-awaited milestone in the battle against the virus. But initial supplies will be extremely limited, with just enough to treat tens of thousands of people.

The drug was authorized for high-risk patients who are most likely to get severe illness.

Pfizer said earlier this month that trial results show the pill cut rates of hospitalization by nearly 90% among patients with mild-to-moderate infections.

A similar pill from competitor Merck is currently under FDA review and has been cleared by regulators for use in the U.K.